Study Links Ozempic and Zepbound to Rare Brain Disorder
By @sharedot · · 7 pages
- Health
- Glp 1
- Nutrition
- Wernicke Encephalopathy
A new study identified 15 cases of Wernicke encephalopathy, a rare vitamin B1 deficiency brain disorder, among users of semaglutide and tirzepatide.
What the study found
Researchers reported in the journal *Clinical Nutrition* that they identified 15 cases of Wernicke encephalopathy — a rare, potentially fatal brain disorder caused by severe vitamin B1 (thiamine) deficiency — among people taking GLP-1 receptor agonists.
According to Baller Alert, eight cases involved semaglutide, the active ingredient in Ozempic and Wegovy, while six involved tirzepatide, found in Mounjaro and Zepbound, with most cases reported during 2023 and 2024. The New York Post reports that researchers examined 195,979 cases in total.
The medications' appetite suppression and tendency to cause nausea and vomiting may reduce nutrient intake enough to create a serious deficiency.
Why the link is plausible but unproven
The connection rests on a plausible mechanism rather than proven causation.
GLP-1 drugs slow digestion and dramatically reduce appetite, and 13 of the 15 patients had also experienced serious gastrointestinal or nutritional problems, including vomiting, appetite loss, malnutrition, or rapid weight loss.
WOWO notes the study does not establish that GLP-1 medications directly caused Wernicke encephalopathy, because the cases were drawn from the FDA's Adverse Event Reporting System, prior medical literature, and the researchers' own medical center — sources that cannot prove cause and effect.
"That's out of millions of people on these medications. So this is rare," said Chicago clinician Karthik Achari, per WOWO, though he added, "it's real, it's serious, and the mechanism makes sense."
Recognizing the warning signs
Wernicke encephalopathy is traditionally marked by a triad of symptoms — altered mental state, trouble walking, and abnormal eye movements — but only two of the 15 patients showed all three, making the condition easy to miss and distinguish from dementia or intoxication.
Baller Alert reports that 11 patients displayed traditional symptoms, and among the 11 with follow-up data, seven suffered lasting neurological complications.
Per the New York Post, as many as 80% of WE cases go undiagnosed, and the condition is treatable if caught early, typically with intravenous vitamin B1 that can stop damage from progressing.
The stakes for millions on GLP-1s
More than one in 10 American adults are now on GLP-1s for weight loss, per the New York Post, so even a rare complication touches a huge population.
Untreated, WE can quickly become fatal in up to 20% of cases, and as many as 85% of survivors develop permanent brain damage, according to the New York Post.
WOWO quotes nutritionist Erin Palinski-Wade: "Don't assume every side effect is just part of being on a GLP-1. Severe or persistent symptoms deserve attention."
She stressed that the drugs shrink appetite, "but that also means people may unintentionally under-eat the very things their bodies need most, especially protein, fiber and fluids."
What comes next
Researchers say additional studies are needed to clarify whether GLP-1 medications, nutritional deficiencies, and Wernicke encephalopathy are truly linked.
The findings are not a reason to stop prescribed GLP-1 drugs, but experts urge patients to keep nutrition and hydration part of treatment — "The drug shrinks your appetite. It doesn't shrink your body's requirements," Achari told WOWO.
Anyone on a GLP-1 who develops persistent vomiting, significant difficulty eating or drinking, confusion, balance problems, or vision changes should contact a clinician promptly.
People with bariatric surgery history or heavy alcohol use may face higher deficiency risk, and foods like pork, beans, lentils, and fortified cereals supply thiamine.